(PRE) Prenetics Global - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 285m USD | Total Return: 77.5% in 12m
Avg Turnover: 3.47M
Qual. Beats: 0
Rev. Trend: 43.8%
Qual. Beats: 0
Warnings
Share dilution 16.7% YoY
Volatile
Tailwinds
Rs Leader, Idiosyncratic Leader
Prenetics Global Limited (PRE) is a health sciences firm headquartered in Hong Kong, specializing in consumer genomics and clinical diagnostics. The company operates CircleDNA, which utilizes next-generation sequencing (NGS) to provide genetic insights, and the IM8 brand for wellness products. Additionally, the company manages the Europa brand for the distribution of sports nutrition products across international markets.
The consumer genomics sector relies on NGS technology to lower the cost of DNA mapping, shifting the business model toward preventative healthcare and personalized nutrition. Unlike traditional diagnostic labs, these companies often utilize a direct-to-consumer (DTC) model to bypass clinical intermediaries and scale data collection.
Investors should consult ValueRay to analyze the companys valuation metrics and industry standing. Prenetics Global Limited was established in 2014 and maintains a significant operational presence in both the United States and Asia.
- Expansion of IM8 consumer health brand scales high-margin wellness product revenue
- Integration of Europa distribution network improves sports nutrition market share and logistics
- CircleDNA genetic testing adoption rates determine long-term consumer health data monetization
- Regulatory shifts in Hong Kong health data privacy impact NGS technology operations
- Strategic pivot from COVID-19 testing to personalized preventative medicine affects margin stability
| Net Income: -76.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 3.20 > 1.0 |
| NWC/Revenue: 48.72% < 20% (prev 142.9%; Δ -94.22% < -1%) |
| CFO/TA -0.11 > 3% & CFO -21.8m > Net Income -76.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (16.0m) vs 12m ago 26.20% < -2% |
| Gross Margin: 56.66% > 18% (prev 0.45%; Δ 5.62k% > 0.5%) |
| Asset Turnover: 54.83% > 50% (prev 16.25%; Δ 38.59% > 0%) |
| Interest Coverage Ratio: -195.3 > 6 (EBITDA TTM -37.2m / Interest Expense TTM 210k) |
| A: 0.27 (Total Current Assets 83.4m - Total Current Liabilities 27.7m) / Total Assets 203.5m |
| B: -2.73 (Retained Earnings -554.8m / Total Assets 203.5m) |
| C: -0.20 (EBIT TTM -41.0m / Avg Total Assets 208.5m) |
| D: 0.00 (Book Value of Equity 25.0k / Total Liabilities 29.0m) |
| Altman-Z'' = -8.41 = D |
| DSRI: 0.16 (Receivables 2.98m/5.61m, Revenue 114.4m/34.7m) |
| GMI: 0.79 (GM 56.66% / 44.73%) |
| AQI: 1.04 (AQ_t 0.58 / AQ_t-1 0.56) |
| SGI: 3.30 (Revenue 114.4m / 34.7m) |
| TATA: -0.27 (NI -76.0m - CFO -21.8m) / TA 203.5m) |
| Beneish M = -2.51 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 17.81 with a total of 239,877 shares traded.
Over the past week, the price has changed by +22.49%,
over one month by -9.23%,
over three months by +0.00% and
over the past year by +77.53%.
Prenetics Global has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy PRE.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.3 | 75.5% |
P/S = 3.0858
P/B = 1.8222
Revenue TTM = 114.4m USD
EBIT TTM = -41.0m USD
EBITDA TTM = -37.2m USD
Long Term Debt = 874k USD (estimated: total debt 2.20m - short term 1.33m)
Short Term Debt = 1.33m USD (from shortTermDebt, last quarter)
Debt = 3.97m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.77m
Net Debt = -57.5m USD (calculated: Debt 3.97m - CCE 61.5m)
Enterprise Value = 227.6m USD (285.1m + Debt 3.97m - CCE 61.5m)
Interest Coverage Ratio = -195.3 (Ebit TTM -41.0m / Interest Expense TTM 210k)
EV/FCF = -10.34x (Enterprise Value 227.6m / FCF TTM -22.0m)
FCF Yield = -9.68% (FCF TTM -22.0m / Enterprise Value 227.6m)
FCF Margin = -19.26% (FCF TTM -22.0m / Revenue TTM 114.4m)
Net Margin = -66.50% (Net Income TTM -76.0m / Revenue TTM 114.4m)
Gross Margin = 56.66% ((Revenue TTM 114.4m - Cost of Revenue TTM 49.6m) / Revenue TTM)
Gross Margin QoQ = 59.47% (prev 59.47%)
Tobins Q-Ratio = 1.12 (Enterprise Value 227.6m / Total Assets 203.5m)
Interest Expense / Debt = 5.29% (Interest Expense 210k / Debt 3.97m)
Taxrate = 21.0% (US default 21%)
NOPAT = -32.4m (EBIT -41.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.01 (Total Current Assets 83.4m / Total Current Liabilities 27.7m)
Debt / Equity = 0.02 (Debt 3.97m / totalStockholderEquity, last quarter 174.6m)
Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -57.5m / EBITDA -37.2m)
Debt / FCF = 2.61 (negative FCF - burning cash) (Net Debt -57.5m / FCF TTM -22.0m)
Total Stockholder Equity = 165.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.47% (Net Income -76.0m / Total Assets 203.5m)
RoE = -45.99% (Net Income TTM -76.0m / Total Stockholder Equity 165.4m)
RoCE = -24.67% (EBIT -41.0m / Capital Employed (Equity 165.4m + L.T.Debt 874k))
RoIC = -24.10% (negative operating profit) (NOPAT -32.4m / Invested Capital 134.4m)
WACC = 6.37% (E(285.1m)/V(289.1m) * Re(6.40%) + D(3.97m)/V(289.1m) * Rd(5.29%) * (1-Tc(0.21)))
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.11 | Cagr: 7.09%
[DCF] Fair Price = unknown (Cash Flow -22.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.51 | # QB: 0
Revenue Correlation: 43.84 | Revenue CAGR: 32.75% | SUE: -0.05 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.49 | Chg30d=-4.26% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-1.77 | Chg30d=-6.63% | Revisions=-20% | GrowthEPS=-31.4% | GrowthRev=+115.1%
EPS next Year (2027-12-31): EPS=-0.68 | Chg30d=+0.00% | Revisions=N/A | GrowthEPS=+61.6% | GrowthRev=+54.3%